A Survival God for the Age of Abundance,” Peter H. Diamandis and Steven Kotler explore what it means to be human in a world ...
From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating ...
Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies ...
Will Spider-Man cross a moral line in Amazing Spider-Man #27? DEATH SPIRAL concludes as Torment pushes our hero to the ...
Researchers showed that an experimental therapy indirectly converted suppressive immune cells into tumor-fighting cells. This ...
A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...
An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including ...
The data to be presented show that Geminii's bioelectronic therapy slowed tumor growth, extended survival, and enhanced the activity of chemoradiation in multiple preclinical NSCLC models without ...
Being able to rapidly reprogram Angry Kitten pods remotely based on the real-time threat environment would be hugely valuable ...
New study reveals metabolic remodeling as an early event in diastolic dysfunction Restrictive cardiomyopathy (RCM) caused by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results